Trials / Completed
CompletedNCT00648895
A Study of the Effect of Nebivolol to Evaluate Its Vasodilatory Effects in Hypertensive Patients
Effect of Nebivolol on Forearm Vasodilation, Nitric Oxide Bioavailability, and Oxidative Stress in Patients With Stage 1/2 Hypertension
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Forest Laboratories · Industry
- Sex
- All
- Age
- 18 Years – 79 Years
- Healthy volunteers
- Not accepted
Summary
The study is designed to compare the effects of nebivolol (10, 20, 40mg/day) with another beta blocker, extended-release metoprolol, at a range of doses. Its purpose is to study the mechanism of action of nebivolol on forearm blood flow, nitric oxide availability and other biomarkers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nebivolol | nebivolol 10mg, 20mg, 40mg daily dosage, oral administration |
| DRUG | Metoprolol ER (TM) | Metoprolol ER 100mg, 200mg, 400mg, daily dosage, oral administration |
Timeline
- Start date
- 2007-11-01
- Primary completion
- 2009-07-01
- First posted
- 2008-04-01
- Last updated
- 2010-09-20
- Results posted
- 2010-09-20
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00648895. Inclusion in this directory is not an endorsement.